南京冠石科技股份有限公司独立董事 关于公司回复 2024 年年度报告信息披露问询函的 独立意见 根据中国证监会《上市公司独立董事管理办法》《上海证券交易所股票上市 规则》以及《公司章程》等有关规定，我们作为冠石科技股份有限公司（以下简 称"公司"）的独立董事，对上海证券交易所《关于南京冠石科技股份有限公司 2024 年年度报告的信息披露监管问询函》（上证公函【2025】0760 号）（以下 简称"《问询函》"）所涉及的相关事项予以了高度重视，本着客观、公平、公正 的原则，经认真核实《监管工作函》所涉及的相关事项并审阅相关资料，基于独 立判断的立场，现就相关问题发表如下独立意见： 问题 3.年报及前期公告显示，公司于 2023 年计划投资 16.10 亿元用于建设 "光掩膜版制造项目"，2023 年 10 月开工建设，2025 年 3 月实现 55 纳米光掩膜 版交付、40 纳米产线通线；截至 2024 年末，该项目累计已投入 10.92 亿元，2024 年实现营业收入 69.47 万元。2023 年至 2024 年，公司购建固定资产等长期资产 支付的现金分别为 4.47 亿元、7.56 亿元；同期末，固定资产 ...

证券代码：605588 证券简称：冠石科技 公告编号：2025-038 问题 1、 年报及前期公告显示，2023 年至 2024 年，公司分别实现营业收入 8.94 亿元、13.59 亿元，同比变动率为-19.26%、51.95%，主要系半导体显示 器件业务收入变化所致；同期该业务毛利率分别为 15.56%、10.25%，同比变动 1.03 个百分点、-5.31 个百分点。分地区看，2024 年公司外销收入 1.67 亿 元，同比增加 244.03%，而毛利率为-2.21%，同比减少 6.39 个百分点且远低 于内销毛利率水平。2024 年公司计提固定资产减值损失 2824.38 万元，主要系 液晶面板产线产能利用率不足，对相关生产设备计提减值 2757.65 万元；2023 年未对相关设备计提减值。 请公司补充披露：（1）2023 年至 2024 年半导体显示器件业务前五大客户、 供应商的名称及关联关系、交易具体内容及金额、往来款余额、期后回款及结 转情况等，说明报告期内该业务营业收入大幅增长、毛利率下降的原因，并结 1 南京冠石科技股份有限公司 关于上海证券交易所对公司 2024 年年度报告的 信息披露监 ...

| 信永中和会计师事务所 北京市东城区朝阳门北大街 联系电话: +86 (010) 6554 2288 | | | | --- | --- | --- | | 8 号富华大厦 A 座 9 层 | | telephone: +86 (010) 6554 2288 | | No.8, Chaoyangmen Beidajie, ShineWing Dongcheng District, Beijing, | 9/F, Block A, Fu Hua Mansion, | 传真: +86 (010) 6554 7190 | | certified public accountants 100027, P.R.China | | facsimile: +86 (010) 6554 7190 | 关于对南京冠石科技股份有限公司 2024 年年度报告上海证券交易所问询函的专项说明 XYZH/2025BJAA19F0026 南京冠石科技股份有限公司 上海证券交易所： 南京冠石科技股份有限公司（以下简称"公司"、"冠石科技"、"被审计单位"）、 信永中和会计师事务所（特殊普通合伙）（以下简称"我们"、"年审会计师"）近 日收 ...

证券代码：605588 证券简称：冠石科技 公告编号：2025-037 重要内容提示： 本期业绩预告适用于净利润为负值的情形。 南京冠石科技股份有限公司（以下简称"公司"）预计 2025 年半年度实现归属于母公司所有者的净利润为-1800 万元至 -1200 万元，与上年同期相比，将出现亏损。 公司预计 2025 年半年度实现归属于母公司所有者的扣除 非经常性损益后的净利润为-2800 万元到-1900 万元。 一、本期业绩预告情况 （一）业绩预告期间 南京冠石科技股份有限公司 2025 年半年度业绩预告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 （二）每股收益：0.28 元。 三、本期业绩预亏的主要原因 全资子公司宁波冠石半导体有限公司光掩膜版项目 2025 年 上半年进入送样验证期，收入规模较小，在建工程转固导致长期 资产折旧摊销等费用大幅增加。 四、风险提示 2025 年 1 月 1 日至 2025 年 6 月 30 日。 （二）业绩预告情况 1、经财务部门初步测算，预计 2025 年半年度实现归属于母 公司所有者 ...

冠石科技（605588）公告，公司预计2025年半年度实现归属于母公司所有者的净利润为-1800万元 至-1200万元，同比出现亏损。预计2025年半年度实现归属于母公司所有者的扣除非经常性损益后的净 利润为-2800万元至-1900万元。全资子公司宁波冠石半导体有限公司光掩膜版项目2025年上半年进入送 样验证期，收入规模较小，在建工程转固导致长期资产折旧摊销等费用大幅增加。 ...

一、募集资金基本情况 证券代码：605588 证券简称：冠石科技 公告编号：2025-036 南京冠石科技股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 中国农业银行股份有限公司 半导体有 39318001040000205 正常使用 经中国证券监督管理委员会《关于核准南京冠石科技股份有限公司首次公开 发行股票的批复》（证监许可〔2021〕2489 号）核准，南京冠石科技股份有限 公司（以下简称"公司"）首次公开发行人民币普通股（A 股）18,275,000 股， 发行价格为 27.42 元/股，募集资金总额为 50,110.05 万元，扣除发行费用 4,523.26 万元后，募集资金净额为 45,586.79 万元。 上述资金已于 2021 年 8 月 5 日全部到位，信永中和会计师事务所（特殊普 通合伙）对上述募集资金到位情况进行了审验，并于 2021 年 8 月 9 日出具了《验 资报告》（XYZH/2021BJAA120480）。公司已与保荐机构、存放募集资金的商 业银行签署了募集资金监管协议，开设了募集 ...

南京冠石科技股份有限公司 关于注销部分募集资金账户的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、募集资金基本情况 经中国证券监督管理委员会《关于核准南京冠石科技股份有限公司首次公开 发行股票的批复》（证监许可〔2021〕2489 号）核准，南京冠石科技股份有限 公司（以下简称"公司"）首次公开发行人民币普通股（A 股）18,275,000 股， 发行价格为 27.42 元/股，募集资金总额为 50,110.05 万元，扣除发行费用 4,523.26 万元后，募集资金净额为 45,586.79 万元。 上述资金已于 2021 年 8 月 5 日全部到位，信永中和会计师事务所（特殊普 通合伙）对上述募集资金到位情况进行了审验，并于 2021 年 8 月 9 日出具了《验 资报告》（XYZH/2021BJAA120480）。公司已与保荐机构、存放募集资金的商 业银行签署了募集资金监管协议，开设了募集资金专项账户，对募集资金实行专 户存储。 二、募集资金管理情况 为规范公司募集资金管理，切实保护投资者权益，根据中国证监会 ...

Group 1 - TaiLong Pharmaceutical plans to apply for the registration and issuance of super short-term financing bonds not exceeding 800 million yuan, with a maturity of no more than 270 days, for purposes including replacing bank loans and supplementing working capital [1] - GuoXin Technology won a bid for a 46 million yuan automotive airbag ignition driver chip project, indicating its growing presence in the automotive semiconductor market [1] - GuoMai Technology expects a net profit increase of 60.52% to 100.33% for the first half of 2025, with a projected net profit of 125 million to 156 million yuan [2] Group 2 - ChangAluminum's subsidiary signed a 165 million yuan contract for the customized construction of a clinical and industrial base for a vaccine project, highlighting its involvement in the biopharmaceutical sector [3] - ZhongSalt Chemical acquired exploration rights for natural soda ash in Inner Mongolia for 929,000 yuan, expanding its resource base [4] - Six Kingdom Chemical announced the resignation of its deputy general manager, which may impact its operational strategy [5][6] Group 3 - FuYuan Pharmaceutical received a drug registration certificate for Bisoprolol Amlodipine tablets, indicating its expansion in the hypertension treatment market [7][8] - GuanShi Technology's subsidiary received a government subsidy of 7 million yuan, which is 45.29% of its net profit for the previous year, enhancing its financial position [9] - XiZhong Technology plans to repurchase shares worth between 75 million and 150 million yuan, aimed at employee stock ownership plans or equity incentives [10] Group 4 - BeiLu Pharmaceutical's subsidiary received approval for the raw material drug Iopromide, which is used as a contrast agent for various imaging examinations [12] - HongHui New Materials obtained a patent for a water-based protective paint for hardware parts, enhancing its product portfolio [13] - BoJi Pharmaceutical's subsidiary received two patents related to high bioavailability formulations, indicating innovation in biopharmaceutical technology [14] Group 5 - ChengJian Development received a cash dividend of 23.625 million yuan from its investment in Huaneng Capital, contributing to its investment income [15] - JiuZhou Pharmaceutical's subsidiary received a drug registration certificate for Sildenafil Citrate orally disintegrating tablets, expanding its product offerings in the erectile dysfunction treatment market [16] - RuiAng Gene's subsidiary received a government subsidy of 176,290 yuan, supporting its operational activities [17] Group 6 - FengFan Technology plans to acquire 100% equity of a subsidiary for 48 million yuan, indicating strategic expansion in the renewable energy sector [18] - AoJing Medical's subsidiary received a medical device production license, allowing it to manufacture absorbable surgical dressings [19] - TaiLin Bio's subsidiary won land use rights for an industrial site, facilitating its high-performance filter project [20] Group 7 - KaiPu Bio received a patent for a method and device for analyzing genomic copy number variations, enhancing its capabilities in molecular diagnostics [21] - Shanghai KaiBao received a drug registration certificate for Phlegm-Heat Clearing Capsules, which can be used in the treatment of COVID-19 symptoms [23] - TuoJing Life received two patents for high uniformity streptavidin applications, improving its diagnostic product stability [25] Group 8 - AnKe Bio's AK2024 injection received approval for clinical trials, marking a significant advancement in cancer treatment [26] - HuanYuan Pharmaceutical expects a net profit of 142 million to 160 million yuan for the first half of 2025, reflecting substantial growth [27] - JinHongShun terminated a major asset restructuring plan due to a lack of consensus among parties involved, impacting its strategic direction [28] Group 9 - HeZhan Energy signed a 177 million yuan contract for the sale of steel-concrete tower structures, indicating strong demand in the renewable energy sector [29] - InSai Group's acquisition plan for an 80% stake in ZhiZheTongXing was accepted by the Shenzhen Stock Exchange, indicating growth in its consulting business [30] - JiuDian Pharmaceutical received a drug registration certificate for Zinc Granules, enhancing its product line in gastrointestinal treatments [32] Group 10 - GuoYao Modern plans to publicly transfer a 51% stake in its subsidiary to optimize resource allocation [34] - GuoYao Modern's subsidiary received a drug registration certificate for Perindopril Indapamide tablets, expanding its hypertension treatment portfolio [36] - ZhongGong International signed a 175 million yuan engineering consulting service contract, showcasing its capabilities in project management [38] Group 11 - China Railway won contracts worth approximately 5.343 billion yuan for overseas construction projects, indicating its strong international presence [39] - JunPu Intelligent signed a framework contract for humanoid robot sales worth about 28.25 million yuan, reflecting growth in the robotics sector [41] - Sinopec's chairman resigned due to age, which may lead to changes in corporate governance [42] Group 12 - JiuFeng Energy's controlling shareholder plans to reduce their stake by up to 0.71%, indicating potential changes in ownership structure [44] - Zhejiang Oriental's subsidiary plans to establish a 1.74 billion yuan equity investment fund, focusing on strategic emerging industries [46] - ChenGuang New Materials received a government subsidy of 26 million yuan, significantly impacting its financial performance [48]

证券代码：605588 证券简称：冠石科技 公告编号：2025-035 根据《企业会计准则第 16 号——政府补助》的相关规定，上述政府补助均 与收益相关，计入当期损益。具体会计处理及对公司 2025 年度损益的影响最终 以会计师事务所年度审计确认后的结果为准，敬请广大投资者注意投资风险。 特此公告。 南京冠石科技股份有限公司董事会 2025 年 7 月 2 日 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、获得补助的基本情况 2025 年 6 月 30 日，南京冠石科技股份有限公司（以下简称"公司"）全资 子公司宁波冠石半导体有限公司获得与收益相关的政府补助 700 万元，占公司 2024 年度归属于上市公司股东净利润绝对值的比例为 45.29%。 二、补助的类型及其对上市公司的影响 南京冠石科技股份有限公司 关于获得政府补助的公告 ...

Core Insights - The polarized lens industry is experiencing significant growth driven by the rapid development of the consumer electronics sector, particularly in smartphones, tablets, and laptops, leading to increased demand for polarized lenses [1][11] - Government support for new materials industries, as outlined in the "Industrial Strategic Emerging Industries Classification Directory (2023)," is further propelling the development of the polarized lens industry [1][11] - The market size of the polarized lens industry has risen from 14.74 billion yuan in 2018 to 31 billion yuan, with expectations for continued growth as downstream application areas expand [1][11] Industry Overview - Polarized lenses, also known as polarizing filters, are used to eliminate direct light and enhance visual clarity, making them essential in various applications including eyewear, camera lenses, and LCD displays [3][11] - The industry has evolved through three stages: a nascent phase from 1995-1999, a startup phase from 2000-2010, and a high-growth phase from 2011 to present, with significant advancements in technology and market competitiveness [5][11] Industry Chain - The polarized lens industry chain consists of upstream raw materials (polarizing films, protective films, adhesive materials), midstream manufacturers who produce the final products, and downstream applications in eyewear, cameras, and electronic devices [7][11] Competitive Landscape - Domestic companies are enhancing their market competitiveness through technological innovation and industrial upgrades, although there remains a gap in high-end products compared to international leaders [13] - Key players in the industry include Ningbo Shanshan Co., Ltd., Hengmei Optoelectronics Co., Ltd., and Shenzhen Sanlipu Optoelectronics Co., Ltd., among others [13][15] Market Trends - The demand for polarized lenses is expected to grow as consumers increasingly prioritize health, safety, and fashion, with applications expanding into emerging fields like virtual reality and autonomous driving [21][22] - International demand for Chinese polarized lens products is rising, supported by the increasing recognition and competitiveness of Chinese brands in global markets [22] - Market concentration is anticipated to increase as leading companies expand production capacities, with Hengmei Optoelectronics planning to add 140 million square meters of polarized lens capacity by 2027 [24]